Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a biotech company with a high chance of approval for their drug to treat mood and psychiatric disorders. With a market opportunity of $1.7 billion and strong earnings, the company has a clear path for success. Despite challenges in manufacturing and potential competition, their lead drug, COMP360, has shown promising results and the FDA's acceptance of their approach bodes well for future success.

Bears say

Compass Pathways is facing significant challenges in its path to regulatory approval and commercial launch. These challenges include the complex and potentially lengthy regulatory process for psychedelics, the need for additional infrastructure for commercialization, and the risk of losing exclusivity after 2034. Additionally, the company may face ESG considerations and regulatory challenges in the future due to the controversial nature of their therapy. While there is potential upside if their therapy is successfully approved and launched, there are also significant risks and uncertainties that may hinder the company's growth and impact their financials, making it a risky investment.

COMPASS Pathways (CMPS) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 10 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.